{"organizations": [], "uuid": "ed4089d6c21af7ffdf786855cf7fd0a933aa2ea3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-recipharm-q4-ebitda-at-sek-226-mil/brief-recipharm-q4-ebitda-at-sek-226-million-idUSFWN1QC027", "country": "US", "domain_rank": 408, "title": "BRIEF-Recipharm Q4 EBITDA At SEK 226 Million", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.058, "site_type": "news", "published": "2018-02-22T14:52:00.000+02:00", "replies_count": 0, "uuid": "ed4089d6c21af7ffdf786855cf7fd0a933aa2ea3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-recipharm-q4-ebitda-at-sek-226-mil/brief-recipharm-q4-ebitda-at-sek-226-million-idUSFWN1QC027", "ord_in_thread": 0, "title": "BRIEF-Recipharm Q4 EBITDA At SEK 226 Million", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - RECIPHARM AB (PUBL):\n* Q4 NET SALES SEK 1.40 BILLION VERSUS SEK 1.33 BILLION YEAR AGO\n* Q4 EBITDA SEK 226 MILLION VERSUS SEK 229 MILLION YEAR AGO\n* PROPOSES NO DIVIDEND FOR 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T14:52:00.000+02:00", "crawled": "2018-02-23T16:08:08.010+02:00", "highlightTitle": ""}